KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma
Published: 26 Jun 2020
Views: 40
Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain
Prof Jesús San Miguel speaks to ecancer in an online interview for the virtual EHA 2020 meeting.
He discusses the KarMMa study initial results. KarMMa looks at idecabtagene vicleucel , a BCMA-targeted CAR T cell therapy, in patients with relapsed and refractory multiple myeloma.
Prof Miguel explains the very positive initial results, providing specific response data, and an outline of the toxicity profile.
Related Videos
Treating patients with multiple myeloma in the real world
Dr Ajai Chari and Prof Roman Hájek
26 Jun 2020
ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine...
Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy
26 Jun 2020
ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for ...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
15 Jun 2020
GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
13 Jun 2020
CANDOR updated results: KdD versus Kd in patients with RRMM according to prior l...
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
13 Jun 2020
Immune checkpoint based approaches in AML and MDS
Dr Naval Daver - University of Texas MD Anderson Cancer Center, Houston, USA
8 Apr 2020
CARTs for the treatment of T-cell malignancies
Dr John DiPersio - Siteman Cancer Center, St. Louis, USA
1 Apr 2020
ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzu...
Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center, Eugene...
17 Dec 2019
Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
13 Dec 2019
